CAI vs NEO: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CAI is the larger of the two ($6.90B market cap): the incumbent the market prices for continued execution (79.14x forward earnings). NEO is the smaller challenger ($2.20B), cheaper on forward earnings (54.14x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CAI vs NEO: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CAI | NEO | What it tells you |
|---|---|---|---|
| Market cap | $6.90B | $2.20B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 79.14 | 54.14 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Price vs 52-week range | 44% of range | 76% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 10.79 | 2.75 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: NEO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CAI and NEO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAI and NEO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAI and NEO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Caris Life Sciences (CAI) do?
Caris Life Sciences, Inc. is an Irving, Texas based precision-medicine company that sequences tumors and blood to guide cancer treatment. Its core service is comprehensive molecular profiling: the MI Profile platform runs whole exome and whole transcriptome sequencing on tissue, while the Caris Assure platform does blood-based profiling (an enhanced version was unveiled in September 2026), and newer assays extend into whole genome sequencing, minimal residual disease monitoring (Caris WGS MRD), hematologic profiling (Caris ChromoSeq) and multi-cancer early detection (Caris Detect). Alongside the clinical lab business, Caris licenses access to its multi-modal molecular and clinical database and runs research services for pharmaceutical partners, which is the second revenue line and the reason the company describes itself as an AI or TechBio company rather than a lab.
What does NeoGenomics (NEO) do?
NeoGenomics, Inc. (Nasdaq: NEO) operates a national network of CLIA-certified, CAP-accredited laboratories that perform cancer genetics testing, plus a full-service sample-processing lab in Cambridge, United Kingdom. Its customers are community oncology and pathology practices, hospital pathology labs, academic centers and pharmaceutical companies, and its menu spans older modalities such as FISH, IHC and PCR alongside next-generation sequencing panels and molecular residual disease testing through the RaDaR franchise. Management reports the company as a single segment with roughly 2,500 employees, and clinical testing supplies the large majority of revenue, with pharma and advanced diagnostics work making up the smaller remainder. Anthony (Tony) Zook took over as chief executive and has been reorganizing the commercial effort, including a dedicated pathology and oncology sales team launched during 2026. On October 5, 2026 the company announced that president and chief operating officer Warren Stone will succeed Zook as CEO on January 4, 2027, with Zook becoming executive chair and board chair Lynn Tetrault stepping down from that role the same day. In mid-October it also expanded its Indica Labs partnership to scale AI-powered digital pathology.
CAI vs NEO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CAI drivers: Reimbursement-driven pricing (ASP); Volume growth and the shift to blood.
- NEO drivers: Mix shift into NGS carries the revenue line; Margin discipline turning into real adjusted EBITDA.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The clearest risk is reimbursement: a large share of recent revenue growth came from price rather than volume, and coverage decisions, rate resets, or payer pushback could reverse that quickly. For NEO, gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation.
CAI or NEO: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CAI if you believe its drivers more; NEO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAI and NEO guides.
CAI vs NEO: the full fundamentals
CAI. Caris's trailing P/E near 18 is flattered by an ~$82 million Q4 2025 profit, since both 2026 quarters were at breakeven, so the market still prices it mainly on sales and on the durability of the pricing gains behind them. That price-to-sales ratio has risen from roughly 5 times in the summer to nearly 9 times after the three-month rally, and BofA lifted its target to $35 from $23 in October. Q3 2026 results are due November 4, 2026, with consensus at ~$0.02 EPS on ~$255 million of revenue.
NEO. With no trailing GAAP earnings, sales and adjusted EBITDA multiples do most of the work here: roughly 2.8 times trailing revenue, about 49 times forward EPS estimates, and roughly 40 times the midpoint of guided 2026 adjusted EBITDA, which only looks reasonable if margin expansion continues for several more years. Balance sheet context matters too, since cash and short-term investments of about $146 million sit against roughly $385 million of convertible principal ($69.0M of 0.25% notes due 2028 and $316.3M of 0.75% notes due 2032), and the shares have ranged from about $7.07 to $20.15 over the past 52 weeks. The 10 analysts Yahoo tracks average a target near $21.85; figures are approximate as of October 16, 2026.
Headline figures (approximate, October 2026): CAI shows revenue (ttm) ~$990M; Q2 2026 revenue ~$264M (+~45% YoY), margins (ttm) ~70% gross, ~10% operating; Q2 2026 gross margin ~68%, net income (ttm) ~$105M, boosted by a strong Q4 2025; Q1 and Q2 2026 each near breakeven, p/e ~18x trailing, ~83x forward (2027 EPS consensus ~$0.37); NEO shows revenue (ttm) ~$766M (four quarters ended June 30, 2026), up ~11% year over year in the latest quarter, q3 2026 revenue (preliminary) ~$209M vs ~$205.9M consensus; NGS revenue up ~28%, margins Gross ~44%, operating ~-5%, net ~-7% (trailing), gaap result TTM net loss ~$52M; Q2 2026 net income ~$2M including an ~$11M debt extinguishment gain.
The bottom line: CAI vs NEO
CAI and NEO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CAI and NEO exposure against your real portfolio. It is not an investment adviser.
Wondering how CAI or NEO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Caris Life Sciences
Ask Walnut's AI anything about CAI and see how it fits what you own.
FAQ
What is the difference between CAI and NEO?
+
Caris Life Sciences, Inc. NeoGenomics, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CAI or NEO the better stock?
+
Neither is universally better. CAI is the larger incumbent; NEO is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CAI or NEO?
+
On forward P/E (as of November 2026), CAI trades at 79.14x and NEO at 54.14x, so NEO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CAI and NEO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CAI vs NEO?
+
CAI: The clearest risk is reimbursement: a large share of recent revenue growth came from price rather than volume, and coverage decisions, rate resets, or payer pushback could reverse that quickly. Growth is already decelerating, from ~79% in Q1 2026 to ~45% in Q2, and analysts expect full-year 2026 revenue of ~$1.03 billion, with quarterly results volatile enough (Q4 2025 revenue of ~$293 million was well above the quarters on either side) that trend-reading is hard. Valuation risk rose sharply with the rally: at ~$8.7 billion the stock trades near ~8.8 times trailing sales and ~83 times 2027 consensus EPS, and insiders have sold shares into the move, including one sale of about $12.1 million disclosed in September 2026. Competition is intense and better capitalized in places, with Foundation Medicine inside Roche, Tempus AI pursuing nearly the same data-plus-sequencing model, and Guardant, Exact Sciences and Grail contesting the blood-based and early-detection frontier. Caris also carries regulatory and legal exposure typical of clinical labs, including a prior ~$2.9 million False Claims Act settlement over billing timing, and lab-developed-test oversight remains an open policy question. Finally, the stock is a recent IPO (June 2025) with a short public track record and a history of large stock-based-compensation charges. NEO: GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation. Reimbursement concentration is the structural exposure: Medicare through MolDx and commercial payors set the prices behind that rising revenue-per-test figure, and evolving regulation of laboratory developed tests could raise the compliance cost of the same menu. Growth is currently priced rather than volume driven, since clinical test count rose only about 2% year over year, so any payor pushback on pricing would hit revenue quickly. On litigation, a purported securities class action captioned Goldenberg v. NeoGenomics (S.D.N.Y., No. 22-cv-10314, filed December 16, 2022, covering purchases between February 27, 2020 and April 26, 2022) was dismissed with prejudice on March 13, 2026, and the plaintiff appealed to the Second Circuit on April 10, 2026; related shareholder derivative actions in Nevada, Florida and New York remain stayed pending that appeal, and the company states the outcome is not currently estimable. Finally, goodwill and intangibles of roughly $795 million sit on a $1.35 billion balance sheet alongside about $385 million of convertible principal, and the 2025 InVisionFirst-Lung write-down showed that impairment of acquired assets is a live possibility. Leadership transition is a newer risk: a change of CEO in January 2027 can disrupt sales execution, and the stock already trades around 49 times forward EPS estimates, so the valuation leaves little room for a stumble, as the 12% one-day drop in October 2026 showed.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CAI or NEO; figures are approximate and dated (as of November 2026). Verify current data before investing.